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Abstract
: Use of patients’ medical data for secondary purposes such asBackground
health research, audit, and service planning is well established in the UK.
However, the governance environment, as well as public understanding about
this work, have lagged behind. We aimed to systematically review the literature
on UK and Irish public views of patient data used in research, critically
analysing such views though an established biomedical ethics framework, to
draw out potential strategies for future good practice guidance and inform
ethical and privacy debates.
: We searched three databases using terms such as patient, public,Methods
opinion, and electronic health records. Empirical studies were eligible for
inclusion if they surveyed healthcare users, patients or the public in UK and
Ireland and examined attitudes, opinions or beliefs about the use of patient data
for medical research. Results were synthesised into broad themes using a
framework analysis.
: Out of 13,492 papers and reports screened, 20 papers or reportsResults
were eligible. While there was a widespread willingness to share patient data
for research for the common good, this very rarely led to unqualified support.
The public expressed two generalised concerns about the potential risks to
their privacy. The first of these concerns related to a party’s competence in
keeping data secure, while the second was associated with the motivation a
party might have to use the data.
: The public evaluates trustworthiness of research organisationsConclusions
by assessing their competence in data-handling and motivation for accessing
the data. Public attitudes around data-sharing exemplified several principles
which are also widely accepted in biomedical ethics. This provides a framework
for understanding public attitudes, which should be considered in the
development in any guidance for regulators and data custodians. We propose
four salient questions which decision makers should address when evaluating
proposals for the secondary use of data
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            Amendments from Version 1
We would like to thank the reviewers and the editor for their 
very helpful comments, which have enabled us to substantially 
improve the paper. We spent a lot of time discussing the 
reviewers’ insightful comments in order to best make 
improvements to the manuscript. Our key revisions include: 
•    Greater justification of the use of core ethics principles to 
understand patient views, and the weaving of these long-
standing principles together with the new theory of social 
licence, within the domain of patient data research. This 
includes a full re-write of the future directions section of the 
discussion.
•    Better explanation of our methods of paper selection, quality 
screening and results synthesis, including reference to 
established methodologies.
•    An up to date section on GDPR as it relates to re-use of 
patient data for research, and further exploration of the 
meaning of privacy in this context.
•    Better consistency in use of terms such as patient data and 
public views.
•    The title has been edited and Supplementary File 2 has been 
updated.
See referee reports
REVISED
Introduction
The use of patients’ medical data for secondary purposes such as 
health research, audit, and service planning is well established 
in the UK, and technological innovation in analytical methods 
for new discoveries using these data resources is developing 
quickly. Data scientists have developed, and are improving, many 
ways to extract and process information in medical records. 
This continues to lead to an exciting range of health related 
discoveries, improving population health and saving lives. 
Nevertheless, as the development of analytic technologies 
accelerates, the decision-making and governance environment 
as well as public views and understanding about this work, has 
been lagging behind1.
Public opinion and data use
A range of small studies canvassing patient views, mainly in the 
USA, have found an overall positive orientation to the use of 
patient data for societal benefit2–7. However, recent case studies, 
like NHS England’s ill-fated Care.data scheme, indicate that 
certain schemes for secondary data use can prove unpopular in 
the UK. Launched in 2013, Care.data aimed to extract and upload 
the whole population’s general practice patient records to a 
central database for prevalence studies and service planning8. 
Despite the stated intention of Care.data to “make major 
advances in quality and patient safety”8, this programme was met 
with a widely reported public outcry leading to its suspension and 
eventual closure in 2016. Several factors may have been involved 
in this failure, from the poor public communication about the 
project, lack of social licence9, or as pressure group Med-
Confidential suggests, dislike of selling data to profit-making 
companies10. However, beyond these specific explanations for 
the project’s failure, what ignited public controversy was a 
concern with the impact that its aim to collect and share data on 
a large scale might have on patient privacy. The case of Care.
data indicates a reluctance on behalf of the public to share their 
patient data, and it is still not wholly clear whether the public 
are willing to accept future attempts at extracting and linking 
large datasets of medical information. The picture of mixed 
opinion makes taking an evidence-based position, drawing on 
social consensus, difficult for legislators, regulators, and data 
custodians who may respond to personal or media generated 
perceptions of public views. However, despite differing results 
of studies canvassing public views, we hypothesise that there 
may be underlying ethical principles that could be extracted 
from the literature on public views, which may provide guidance 
to policy-makers for future data-sharing.
Governance and legal framework of data use
Since 2018, the General Data Protection Regulation (GDPR) has 
governed the use of patients’ medical data in the EU and UK, 
superseding the Data Protection Act in the UK (1998). GDPR 
covers personal, or patient identifiable data in the UK, and 
defines pseudonymised data, which can be traced back to the 
individual using a study or database specific ID code, as personal 
data. Patient data can be used for direct care or audit and health-
care quality improvement projects without consent as these are 
seen as primary use of data. Research, however, is a secondary 
use of such data, as it is a use different from the originally 
declared purpose of data collection. Research organisations 
thus need a “legal basis” for processing the data even when 
identifiers are stripped, if individuals are still potentially re- 
identifiable by a pseudonymisation code11. One such legal basis is 
individual consent for use of the data in this way, and a second 
is “a task in the public interest”. For research, such processing 
may be justified in terms of research for the public good, as long 
as appropriate safeguards are in place to reduce potential harms 
to the data subject and ensure respect for the principle of data 
minimisation.
Reducing potential harms to the data subject involves taking a 
range of precautions to reduce the risk that an individual patient 
could be re-identified. Removing the pseudonymisation code 
and aggregating the data to a level at which re-identification is 
not possible is the surest way of reducing such harm, but 
often renders the data less usable for research purposes and 
destroys the ability to link the data to other sources of health 
information. Research teams usually robustly protect patient 
data with computing security systems, which do not allow the 
data to be downloaded, or unapproved datasets to be uploaded and 
linked to the sensitive data. They also ensure only trusted and 
trained users are permitted access to the data. If data are to be 
released to the public, this is usually done only after data have 
been aggregated so that they have become truly anonymous.
Striking a balance
While it is clearly important to make sure patient privacy is 
protected, it is also argued that the societal benefit of medical 
research using patient data, should be given ethical weight. This 
is argued on the basis that harms to patients may occur where 
these rich data sources are not used to improve our understanding 
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of health conditions and treatments12. While individual privacy 
and societal benefit are often portrayed as being in opposition, 
for the future of health data research, a way to achieve both to the 
satisfaction of patients, clinicians, legislators and researchers 
must be found. Recent work has sought to identify the key issues 
of patient views on data-sharing13. However, few syntheses of 
patient views have additionally aimed to identify the implicit 
reasoning on which patients rely to justify the responses they 
give. Identifying a framework which describes the core moral or 
ethical values underlying public views may help us to predict 
the reaction of the public to new data sharing challenges in the 
future. Since the tension between data sharing and privacy is an 
ethical tension (to the extent that it involves what states of affairs 
ought to obtain, morally speaking), we are interested in the 
ethical dimensions of such patient reasoning. To this end, we 
propose to draw on core principles of biomedical ethics. First 
suggested in 1978 and 1979 in two forms, by Beauchamp and 
Childress for ethical conduct within medicine14, and in the 
Belmont report15 for ethical conduct in healthcare research. 
Core principles include the concepts of respect for autonomy, 
beneficence, non-maleficence, and justice. A similar set of 
principles were applied to information technology research in 
science and technology by Menlo in a 2012 report16. We aimed 
to use these widely accepted principles as a tool to identify 
underlying themes expressed in patient views, and as a lens 
to discuss the findings. We also aimed to bring together these 
core principles with the newly adopted social licence theory 
for patient data research9. This theory suggests that by volun-
tarily adhering to social codes of trustworthy and responsible 
behaviour that go beyond legal or regulatory frameworks, and 
by honouring additional safeguards, organisations can engender 
trust from the public for schemes which may initially be 
controversial.
In this study, we therefore aimed to systematically review and 
thematically analyse UK and Irish studies exploring patient 
and public views on patients’ medical data being used for the 
secondary purpose of research, and aimed to understand and 
map these views onto established biomedical ethical principles. 
We aimed to make suggestions for consideration by ethics 
committees and regulators to ensure that such research operates 
in a transparent and trustworthy way, with the aim of maximis-
ing the potential for the public to grant a social licence for such 
research to operate.
Methods
We followed the PRISMA guidelines for the conduct and report-
ing of this review17.
Search strategy
We searched PubMed, Web of Science, and Scopus between 
03/10/16 and 11/10/16 using the following search string: 
(Public OR Patient OR People) AND (Attitudes OR Knowledge 
OR Opinions OR Views OR Perceptions) AND (“Care.data” OR 
“Electronic Health Record” OR “Electronic Health Data” OR 
“Electronic Medical Record” OR “Electronic Medical Data” OR 
“Personal Health Information” OR “Personal Health Record” OR 
“Electronic Patient Information” OR “Electronic Patient Data” 
OR “Electronic Patient Record” OR “Data linkage” OR “Data 
sharing”) AND (Research). We restricted our search to pub-
lications from 2006–2016 inclusive. We also searched the 
grey literature using the search string: “public attitudes” AND 
“sharing” AND “health data” on Google (in June 2017). The first 
20 results were selected and screened. The following inclusion 
criteria were then applied: 
1.    Empirical studies using any methods reported as a full 
length peer review manuscript or published report.
2.    Healthcare users, patients or the wider public as 
participants
3.    Examining views, attitudes, opinions, perspectives, 
thoughts, awareness or acceptance about the topic of use 
of patient data for medical research.
    3a. Patient data for medical research includes 
electronic hospital records, electronic general prac-
tice records, and data extracted from these records, 
for example cancer registries and national disease 
databases (summarised as patient data or EHRs).
4.    Studies using a UK or Irish sample, written in English. 
We chose to keep our review to these two countries 
because of similarities in their socialised healthcare 
systems, and because of the well-established use of 
patient data within these jurisdictions.
Studies were excluded if they were: 
1.    Focused more broadly on digital technologies in health 
care where the focus was on use of digital methods or 
records rather than public attitudes
2.    Focused on patient and practitioner attitudes to 
analogous areas such as biorepositories, genetic testing 
and genomic research or personal data not exclusively 
related to health.
3.    Non-empirical reviews of legislation, policy, ethical 
challenges etc.
Using these criteria, the articles extracted from the literature 
search were screened based on their title, then abstract (by author 
JS), then finally the choice of full text papers for the review was 
undertaken by two authors (JS and EF).
Quality Assessment
Study quality was assessed using the Mixed Methods Appraisal 
Tool (MMAT)18. This tool was designed for the appraisal of 
studies in mixed methods systematic reviews and attempts to 
appraise the quality of methodology, rather than the quality of 
reporting. All studies meeting the inclusion criteria above were 
assessed using six criteria. The first two criteria are the same for 
all studies: is there a clear research question or objective, and 
does the data collected address the research question or objective. 
A further four questions were specific to the study type. Studies 
were given a score out of six depending on how many of the six 
criteria they met, and were rejected if they did not meet at least 
the first two criteria. Two papers were excluded on the basis of 
scoring zero on all criteria.
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While quantitative papers are generally seen as of higher 
quality, we believed that the in-depth exploration of human 
reasoning for participant perspectives and decisions, illustrated 
in the qualitative studies, could offer a greater understanding to 
underpin our moral and ethical interpretation. Thus we treated 
quantitative and qualitative studies as having equal value in the 
analysis if they met quality criteria. 
Data extraction
We extracted author names, dates, location, type of study (quali-
tative or quantitative), methods used, number of participants, 
their backgrounds or roles, ages, genders, and the study findings 
which fitted into the themes relating to research questions 
reported below.
Synthesis of results
The full text of eligible articles was read iteratively by two 
authors (JS and EF) with the aim of extracting coherent themes. In 
the first iteration of reading and coding the results of the papers, 
nine questions arose, which formed the basic direction of the 
inquiry.
1.    Are patients/public aware of electronic health records 
(EHRs) and their secondary uses?
2.    Are patients/public concerned about the privacy and 
security of their medical data?
3.    Are patients/public willing to share their medical data for 
research, policy and planning?
4.    What consent model do patients/public prefer?
5.    How does data being identifiable or anonymised affect 
patient/public preferences?
6.    Which organisations are most and least trusted with 
patients’/public data?
7.    What are the reported perceptions of risks and benefits of 
sharing medical data for research?
8.    Are there any other ways in which willingness to share 
could be increased?
9.    Is there any differences between demographic groups 
concerned with the sharing of EHRs?
A framework19 was created with a column for each of the nine 
questions and data was extracted from each study where it fitted 
into these categories. Following this data extraction, the two 
authors (EF and JS) discussed refining and combining extracted 
data into as smaller number of themes. In a second iteration of 
data extraction, authors re-read articles and extracted data into 
seven themes. For interpretation and synthesis, a data driven 
approach was taken, trying to make meaning from first order 
data reported in the papers (i.e. statistics or participant quotes). 
Where themes were populated mainly by summary of quantitative 
data, a straightforward report of papers’ findings is given.
Where contributing papers were mainly qualitative e.g. in the 
Trust theme, we undertook a deeper analysis directed by Braun 
and Clarke’s guidance on qualitative thematic analysis20, an 
approach recommended for meta-synthesis by Dixon-Woods 
et al.21 and Thomas and Harden22. By taking an interpretive 
approach23 to the synthesis of the data, we examined “the 
underlying ideas, assumptions, and conceptualisation – and 
ideologies – that are theorized as shaping or informing the 
semantic content of the data” (p.84)20. This was shaped and 
directed by Beauchamp and Childress’ four principles of 
bioethics14, which enabled us to gain a better understanding of 
the emerging moral meaning, and moral values conveyed by the 
study participants in these themes. As far as the authors are 
aware, there are no pre-existing applications of this framework 
to study patient attitudes. However, this general approach 
has been taken before using The Belmont Report to identify 
stakeholder views on technology-enabled research24. While the 
four principles have drawn criticism elsewhere25,26 they continue 
to be extremely influential in evaluations of ethical dilemmas 
in health care, and a useful framework with which to identify 
moral values in participant decision-making.
Results
A total of 13,472 peer-reviewed papers were found through 
the systematic search, as well as 20 reports found through the 
grey literature search. Of these, 20 UK and Ireland based papers 
met the inclusion criteria and were included in the review4,27–45 
(Supplementary File 2). Studies which reported time periods 
indicated that data was collected from 2004 to 2016, although 
seven studies published between 2011 and 2016 did not report 
the data collection period. Research participants included 
patients, service-users, lay persons, those living with chronic 
conditions, and the general public ranging from 16 years of 
age to over 75. Five of the studies included the views of health 
researchers, health professionals, industry experts, NHS managers 
and other key stakeholders. Seven of the papers were quanti-
tative, using surveys or structured questionnaires. Ten of the 
studies were qualitative, using focus groups and one-to-one 
interviews, and there were three mixed methods studies. Details of 
studies are reported in Table 1.
Quality assessment
Studies’ quality scores ranged from 3 to 6 out of a possible 6, 
scores of individual studies are shown in Table 1. Two studies 
which otherwise met inclusion criteria were rejected on the basis 
of quality and do not appear further in the results46,47.
Themes elicited from the studies
The seven themes identified in and elicited from the studies were: 
Knowledge and Awareness of Electronic Records; Willingness to 
Share; Privacy; Trust; De-identification and Consent Preferences; 
Routes to Securing Trust; and Demographic Differences. The 
contribution of each study to each theme is shown in Table 2.
Knowledge and awareness of electronic records
Generally, knowledge of the content and electronic collection 
of GP records among respondents was high. One quantitative 
study reported that a moderately high proportion of respondents 
at 59% had prior awareness of EHRs43. Another quantitative study 
reported that levels of understanding of the information recorded 
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Table 2. Contribution of Studies to Themes.
Study Knowledge and 
Awareness of 
Electronic 
Records
Willingness to 
Share Data
Privacy Trust De-identification 
and Consent
Routes to 
Securing 
Trust
Demographic 
Differences
Audrey et al. 2016 X X X
Baird et al. 2009 X X X X
Barrett et al. 2006 X X X X
Buckley et al. 2011 X X X X
Campbell et al. 2007 X
CM Insight and 
Wellcome Trust 2013
X X X X X
Clerkin et al. 2013 X X X
Grant et al. 2013 X X X X
Haddow et al. 2011 X X X X
Hays & Daker-White  
2015
X X X X X X
Hill et al. 2013 X X X X X X
Ipsos Mori, MRC 2007 X X X X X X X
Ipsos Mori, MacMillan, 
CRUK 2016
X X X X
Ipsos Mori, Wellcome 
Trust 2016 One Way 
Mirror
X X X X X
Ipsos Mori, Wellcome 
Trust 2016 Monitor 
Report 3
X
Luchenski et al. 2013 X X
Papoutsi et al. 2015 X X X X X
Riordan et al. 2015 X X X
Spencer et al. 2016 X X X
Stevenson et al. 2013 X X X X
by GPs were high without giving exact numbers30. One quali-
tative study reported that across groups, participants had a good 
awareness of the kind of information that usually held in general 
practice records4. Nevertheless, participant awareness of specific 
uses of routinely collected patient data was low. For instance, 
two quantitative studies reported that 82%29 and 80%39 of the 
general public had not heard of the National Cancer Registry, while 
another study reported that patients were not only inadequately 
informed about their right to opt-out of Care.data, but were also 
unaware of the project35. Two studies indicated that understand-
ing of medical research using patient data was low32,37, while 
another suggested that participants were unaware of how their 
data was currently used36. Another demonstrated limited public 
grasp of a range of concepts related to patient information use, 
such as de-identification, data science, the benefits of aggregate 
data, and the role of private companies in the healthcare system. 
People with lower understanding of these issues were more likely 
to have concerns about commercial access to health data39.
Willingness to share
In many of the studies, participants expressed willingness to 
share their EHRs for secondary purposes like research, policy 
and planning, despite the range of concerns discussed below. 
Among the quantitative studies, support for sharing patient data 
with researchers was reported at 68.7%30, 77%40, 81.4%42, and 
83%37. In the qualitative studies, participants identified will-
ingness to share their EHRs for secondary purposes with the 
“common”, “greater” or “public good”4,27,28,32,37; “social 
responsibility”44,45; “altruistic attitudes”28; and “giving some-
thing back”33 to “other people” or “future generations”4,28,34–36,44. 
For example, in one study it was stated: 
 I’m saying yes because I think there is a greater good. 
(Participant 1, Group 2,36)
Such reasoning was largely predicated on the understanding that 
medical research using EHRs could lead to benefits such as the 
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improvement of healthcare services, or innovations in the diagnosis 
and treatment of disease. For example: 
I think if you are going to do something, eczema, allergies, 
something that affects one in five people you need the huge 
samples in order to do it. (Patient Interview L2,45)
And: 
. . . because you never know where research is going to go. 
You don’t know where some brilliant young scientist’s mind 
linking up different things, you know. And you cannot put a 
halt on that, a break on that. (Di, Focus Group 1,34)
Moreover, it was also understood that using EHRs might be a 
better way of doing and facilitating research:
. . . I mean it’s a better system than it is at present, because 
you are going to get 100% response that way or near 
enough and the present system is that the GPs put out things 
on spec to people that may want to join this thing and they 
may get a very low return. (Male, Patient Focus Group 3,33)
From these studies, the “common good” appeared to consist 
of the collective public health benefits brought about by the 
improvement of the services, practices and methods of healthcare 
through secondary uses of data. Willingness to share appears 
connected to idea of an individual having a personal respon-
sibility, obligation or duty to help bring about this common 
good: 
Once you have been in receipt of the excellent kind of 
care and treatment that I’ve had, I think you have a social 
responsibility that if you can help the next generation by 
having your information provided to the researchers to [do] 
some good. (Focus Group 3,44)
Privacy
Despite the general willingness to share EHRs for second-
ary purposes, many qualifying concerns were raised by 
participants27,28,32–39,42,44,45. This suggests that although the shar-
ing of EHRs is largely seen as being for the overall common 
good, participants believe that it also has the potential to create 
new risks, and increase existing ones. The various perceived risks 
involved in sharing EHRs were well described by participants. 
These included routes to harm like hacking35,42, unintentional data 
leakage or loss35, unauthorised access42, access without explicit 
consent27, errors in medical records42, re-identification34, 
aggregating data to a group’s disadvantage34, and access, use 
and governance of data by the government34. Participants also 
listed perceived harms as a result of adversaries gaining access 
to data, these included: identity theft42, unnecessary stigmatis-
ing judgements in clinical settings42, consequences for employ-
ment, pension eligibility, or insurance costs4, social discomfort 
and community embarrassment4, and the use of EHRs for 
financial gain36. The breadth of this list demonstrates the structural 
complexities of the particular, concrete situations which study 
participants imagine may arise from the misuse of their data. 
Several studies connected these risks and the concept of 
privacy4,27,28,32,39,42,44. Privacy was generally conceptualised 
by participants as a process of control: 
Seemingly radical idea: let PATIENTS control who can access 
their personal medical data! #caredata. (Twitter user,35)
Participants frequently identified two key elements that could 
be determined in relation to their information. The first was 
whether information is revealed to, or accessed by another party: 
My concern is exactly that: who has access to my files and 
how can we make sure that only those I want to have access 
would have access? (Focus Group 12,42)
A second element concerned how this information should be 
used, or analysed after it being revealed to another party:
At the end of the day, it’s not who has access to it all, it’s 
how they use it, I think is the main concern for us, for 
everybody. . . how they use it. (Person with MS, Focus 
Group 7,28)
These two factors were necessary components in identifying 
what was and was not acceptable when it came to unlocking the 
potential of patient data.
Trust
Views on storing and using patient data were linked to the kind 
of trust or distrust the public had in an organisation or individual 
using or accessing the data.
You have to trust people. (Fiona, Focus Group 2,34)
Where participants distrusted organisations who would handle 
their data, this generally occurred along two lines: 
1.    Distrust of a party’s ability, or competence, to ensure 
data security.
2.   Distrust of a party’s motivations.
In terms of a party’s competence, participants were likely to 
agree that a particular party could store and use their data in 
principle, but were concerned that they are not able to guaran-
tee the level of security required by such personal data due to 
institutional incompetence. One such party was “the NHS”36,42. 
For example, in one study a majority of respondents (71.3%) 
voiced doubts about the ability of the NHS to guarantee the 
security of EHRs, yet 53.5% of those respondents would 
nevertheless support the development of a national EHR42. On 
the incompetence and inefficiency of the NHS, participants 
stated the following things: 
 I just have very little faith in the way that the NHS handles 
databases. I don’t think it’s got a very good record. . . (Focus 
Group 3,42)
 Always thought that [the NHS] would mess it up (Focus 
Group 11,42)
 #NHSPatientdata scheme handling a ‘masterclass in incompe-
tence’ #CareData #NHS [link] [link]. (Twitter user,35)
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However, in some qualitative studies, participants expressed a 
generalised trust towards the NHS, especially when concerning 
GPs: 
 I mean I can trust the doctors and all . . . but other people, 
no. Once it leaves the NHS, I’d be wondering where it’s 
going and who’s looking at it. (Participant 19,44)
 . . . once it goes out of the NHS, the NHS have no control 
over it whatsoever. (Di, Focus Group 1,34)
Nevertheless, and perhaps surprisingly, participants tended to 
say that the data would be safer in the hands of the NHS or a 
public sector organisation, and that private companies were less 
likely to be as diligent in their handling of it39.
When it came to an organisation’s motivation, there was a strong 
sense that any access and use of the data must be for the good of 
the individual patient or the common good of the public. Many 
studies indicated that any kind of data handing for private 
interests would be unacceptable32–36,42,45. In terms of the possi-
ble consequences, a recurring theme was that if a party had the 
wrong competences or motivations, this could lead to substan-
tial harm on both an individual or collective societal level. For 
instance, as the following quote illustrates, it was identified 
that the private profit motivations of insurance and marketing 
companies could lead to harms on an individual level: 
One of my fears was if it somehow goes astray from there 
and somebody, for instance, like insurance companies, get a 
hold of it they could use it to their advantage and the patient’s 
disadvantage. (P2, Focus Group,45)
However, direct harm to individuals is not a necessary factor in 
determining the wrongness of certain motivations. It was also 
indicated that even if no particular individual is disadvantaged, 
allowing those with private interests to access public data can 
constitute a collective harm. This is because there is a strong 
sense that data should only be used to benefit either individuals: 
Financial gain comes into it then so why should you then let 
them look at your records? They are going to gain out of it 
and you’re not. . . (Participant 2, Group 2,36)
Or, the public at large: 
 If there was a large commercial company. . . [that] had free 
and easy access to people’s medical records I don’t think 
that would be right. It would further their research into the 
particular drug or treatment, but it’d also further their prof-
its that would be wrong. But if it was for medical research 
for everybody then that would be different. (Participant 6, 
Group 3,36)
Despite this firm belief, several of the studies indicated a tension 
in the status of pharmaceutical companies whose products are 
indispensable to medicine and the health of populations, but 
which ultimately operate in a profit driven capacity28,33,36,37,42. As 
Grant et al.33 write, this leads some participants to see the involve-
ment of pharmaceutical companies as a “necessary evil”.
This dimension was further discussed in the grey literature 
which revealed a more nuanced picture regarding public opinion 
towards the commercial uses of data. Support for commercial 
access to patient data raised from 54% to 61% when taking 
into account the possibility of new treatments being discovered39, 
and participants were indifferent to who conducts research so 
long as the objective is to increase knowledge around the causes 
and cures of ill health32. This suggests that participants recog-
nise that not all commercial uses of data are done from purely 
privately interested motivations, but that at least in part can involve 
public motivations too. In explaining the apparent reluctance 
of the public to accept certain private interests so as to ensure 
public benefits, one study identified that participants did not 
currently feel that they could evaluate the motivations of com-
mercial organisations who would use the data, which created an 
unclear conception of what the public could stand to gain 
through these uses of data. As a result, participants tended to 
fall back into wider assumptions, personal beliefs and prejudices 
regarding private companies39.
De-identification and consent preferences
In the quantitative studies, 67.5%30 of respondents in 2011 and 
91%43 of respondents in 2015 were clear that although it was 
fine for researchers to access their EHRs, they still expected to 
be asked for consent when their identifiable data was accessed 
for secondary purposes. However, there was less consensus 
over de-identified data, with 83.7%30, 51%31, and 49.3%43 of 
respondents reporting willingness to share or agreement that 
de-identified patient data could be extracted without consent. 
Reasons for concern around de-identification also emerged in 
the qualitative studies where participants questioned what would 
qualify as identifying information42, whether de-identification 
could be achieved effectively37,42, whether it was sufficient 
for the elimination of consent27,36 and highlighted the risks of 
re-identifying individuals32,35.
Several studies also indicated substantial concerns about the 
opt-out rather than opt-in model of consent which was pro-
posed in schemes such as Care.data35,45, while others noted that 
participants generally thought about consent along opt-in lines 
when asked for their opinions27. Participants expressed worries 
about whether people would really understand the concept of 
opting-out45. They also criticised opt-out on the basis that it 
was unethical and illegal35. However, in one quantitative study 
52% of the general public supported the opt-out method of 
collection for the National Cancer Registry38, while a minority of 
participants in another study acknowledged that opt-out might be 
a better option given the impracticalities of opting-in37.
The problem of selection bias and its connection with 
consent arrangements was explored in three studies27,36,42. In 
two studies, some participants identified the potential for bias 
if the information which was gained was neither accurate nor 
balanced27,42: 
If they’ve got mental health illness then. . . that might affect 
their willingness, so it might be hard to. . . gather enough 
information. I think that might be biased. . . (Male ID47,27)
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Participants also recognised that larger, more representative 
samples could be gained by an opt-out process: 
You are going to get 100% response that way, or near enough 
and the present system is that the GPs put out things on 
spec to people that may want to join this thing and they 
may get a very low return. (Male, Patient focus group 3,33)
This prompted discussion in one study about the importance 
of mitigating the requirement of consent by de-identifying 
information: 
There is certain situations where you might be able to, it 
might be acceptable to ask or it might be acceptable just to go 
ahead and get it—as long as it wasn’t directly linked back to 
you as a person, it would be alright. . . (Female, ID6,27)
In another study36, after receiving presentation about selection 
bias, participants recognised the difficulties faced by researchers. 
Interestingly, when asked if this information had changed their 
opinion about using health data without consent, several partici-
pants out of the group who at first indicated reluctance, reported 
that they had indeed changed their minds. A quantitative study 
showed that a substantial minority of respondents (20%)37 
believe that consent may not be needed if it is not practical to 
obtain.
Routes to Securing Trust
Across studies, participants identified several different infra-
structure arrangements which could increase willingness to share 
patient data for secondary purposes and trust in their use for 
public benefit. Participants indicated that no single organisation 
should be responsible for deciding who could access and use 
their EHRs, rather a committee of stakeholders was called for, 
including Caldicott Guardians, research consultants, members 
of the public, GPs, social services staff, charities, funders, 
and patients.28,34. It was also felt that greater transparency was 
needed in regards to safeguarding processes and data sharing 
arrangements35,44, including stiff penalties or fines for misuses 
of data35,39; the publication of results39; clear guidelines and laws 
to regulate access and use of data35; and, regulators and parties 
accessing data to be held to high standards39. Several studies 
also indicated that participants wanted a better understanding 
about the nature of EHR initiatives, medical research37, the 
purposes and benefits of using data33,37, de-identification and 
aggregation39, and also why in some situations consent might not 
be practical39. More generally, participants wanted the security 
of records to be ensured33,39; for private profit to be capped39; and 
denial of third party access39. In several studies, participants 
also indicated their preference to retain granular control over 
the data in their EHR using an explicit opt-in consent scheme, 
the right to withdraw at any time and ability to tailor sharing 
preferences28,33,35,44.
Despite the breadth and diversity of participant suggestions 
to increase trust, it might be that no single, or any specific 
combination of strategies will amount to a gold standard of 
acceptability or social licence. One study found that no particu-
lar safeguard made sharing data with commercial companies any 
more acceptable than any other39. However, in the same study, 
participants were significantly less likely to endorse sharing 
data without any safeguards (49% agreed) compared to with 
safeguards (56–64% agreed, depending on the safeguard). This 
suggests that the precise nature of the safeguard may be less 
important to improving willingness to share than knowing that 
there are safeguards in place.
Demographic differences
We aimed to ascertain whether the included studies indicated 
a level of heightened concern, worry or fear among one or more 
specific social groups and we restricted this analysis to quan-
titative studies which could enable such contrasts. Although 
participants were asked a variety of different questions across 
each survey, we evaluated responses on the basis of whether 
they indicated an overall negative or positive attitude towards the 
sharing of EHRs for secondary purposes such as research. For 
example, in Papoutsi et al.42, participants were asked if they 
would be more worried about the security of their informa-
tion if it were part of a national EHR register, while Buckley 
et al.30 asked if they would allow their EHRs to be provided to 
researchers without their explicit consent. Despite the differ-
ing approaches of these questions, we concluded that a response 
indicating more worry about security, and one indicating less 
likelihood of granting researchers access without explicit 
consent, were comparative insofar as they represented a negative 
attitude towards sharing of EHRs.
Within quantitative studies, findings were reported across a whole 
range of demographic differences. Between studies, compari-
son could only be made between age range, levels of education, 
and ethnicity. We found conflicting findings in all three of these 
categories. We found evidence that both younger people and older 
people would favour sharing their data, that people with lower 
levels of education were both more and less likely to agree to 
sharing without consent, and that people of non-white ethnicity 
were both more and less likely to support EHRs and think of 
them as secure. For a full break down of the demographic results, 
see Table 3.
Discussion
We found that knowledge of the content and collection of patient 
data in EHRs was reasonably high, but knowledge about the 
secondary uses, such as data sharing for research, was low. 
Nevertheless, when asked, participants were generally willing to 
share their data for the “common good”, subject to safeguards. 
Willingness was qualified with concerns about privacy which 
participants generally equated with the idea of control. This 
conceptualisation of privacy as control closely corresponds 
to the idea that informational privacy is the ability of an 
individual to determine for themselves what happens with certain 
information relating to them48,49. This particular definition 
has attracted criticism insofar as it difficult to capture what 
constitutes “certain” information50. Within the legal and philo-
sophical literature it is generally accepted that what constitutes 
an individual’s determination is whether or not information is 
communicated to other parties, however, our analysis suggests 
that the public also believes that their privacy can be violated not 
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Table 3. Study findings on Demographic Differences.
Group Indicative of Negative Attitude Indicative of Positive Attitude
Age Compared to those aged 25–34, respondents between 
the ages of 35–64 were more likely to report they would be 
worried about the security of their records as part of a national 
EHR42.
Increase in age by each 10 year increment was 
significantly associated with an increased likelihood of 
reporting that any info can be provided to researchers 
without asking for consent30.
Compared to those aged 25–34, respondents over 35 years 
old were more likely to report less confidence in the ability of 
NHS security and were less likely to report that EHRs were 
equally or more secure than paper records42.
Older people (55–64, 65+) were more likely to find 
a drug company conducting research into the 
unwanted side effects of a drug using deidentified 
data to be more acceptable than younger people 
(16–24, 25–34, 35–44, 45–54)39.
Older people were increasingly more likely to report that they 
would not be in favour of a national EHR compared with 
25–34 year olds41.
Those aged 55–64 tended to agree that research 
should be conducted by commercial organisations 
if there is a possibility of new treatments being 
discovered in comparison to 16–24s and 35–44s39.
In the general public, support for the opt-out 
collection method was higher in over 55s (58%) than 
18–34 (49%) and 35–54s (49%)29. 
Those over 55 were more likely to say to say that they 
would allow their data to be used for medical research 
compared to those aged 16–2437.
Education Respondents with lower educational qualifications were more 
likely to expect to be asked for explicit consent before their 
deidentified records were accessed43.
Compared with participants with higher degrees, 
individuals with no academic qualifications were less 
likely to say that they would worry about security if 
their record was part of a national EHR42.
Compared with completion of third level education, 
completion of only primary level education was 
associated with increased likelihood of reporting 
that any info can be provided to researchers without 
asking for consent30.
Socioeconomic 
Status
Those of a lower socioeconomic status were more likely to be 
concerned about privacy29.
Those in the lower socioeconomic group DE (43%) 
were more likely to support companies using health 
data collected in the NHS to help target health 
products at different groups of people39.
Those in socioeconomic groups C2 and DE were less likely 
than those in AB and C1 to view the use of health data as 
having a potential benefit to society32.
Those in the lower socioeconomic group DE were less likely 
to say they trusted a variety of people with their health data; 
say that the advantages outweigh the disadvantages of using 
health data in research; and say that researcher can use data 
without prior consent than Abs37.
Those in socioeconomic groups C1 and C2 were less likely 
than ABs to allow their health data to be used37.
Those in socioeconomic groups DE (46%) were less likely 
to support commercial organisations to undertaking health 
research with health data than AB (62%)37.
Those in socioeconomic groups DE (26%) were 
less likely to support commercial organisations to 
undertaking health research with health data than AB 
(30%)37.
Ethnicity Black British respondents were more likely to say they would 
not support the development of a national EHR system 
compared with White British respondents41.
Compared with White British groups White non-British, 
Asian, British Asian, Black-African, Caribbean, and 
British Black groups were more likely to say that EHRs 
are as secure, or more secure that paper records42.
Respondents identifying as belonging to an ethnic group 
other than White British were more likely to expect to be 
asked for explicit consent before their deidentified records 
were accessed43.
Those whose ethnicity was not White British were more likely 
to be concerned about the invasion of privacy29.
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just in the sharing of their information, but in the subsequent use of 
that information too (e.g. using personal information for profit). 
Participants feared adverse outcomes less when they trusted both 
the motivation of research organisations to conduct research 
for the common good, and the competence of organisations to 
handle the data safely and without compromise. When evaluat-
ing opinions on consent mechanisms, findings suggested that 
educational and deliberative research into public opinion may 
provide different answers from snapshot surveys. This is because 
after weighing up a range of issues involved, participants could 
often see the benefit to research quality of opt-out schemes. Results 
suggested a range of mechanisms to increase public trust, and 
the overarching theme here was transparency of motivation, data 
handling and data flow.
Core Ethical Principles
The foundational moral principles which Beauchamp and 
Childress14 identify as paramount to governing biomedical 
practice, and which Belmont identified as important for medical 
research15 can be used as a lens for understanding and interpret-
ing these findings. Where we find that public reasoning maps to 
these basic principles, it can be inferred that these core ethical 
principles are a constituent part of non-specialist thinking 
about the ethical practicalities of healthcare and medicine. This 
in turn identifies these ethical principles as a suitable structure for 
guiding reasoning on future data sharing challenges. 
For instance, the included studies indicate that there is a wide-
spread willingness to share EHRs for secondary purposes, in 
principle. This willingness was held on the basis that, using and 
accessing data in such a way can bring about benefits which 
are in the interests of all individuals, or in other words, the 
“common good”. The basis of this belief may be the general 
expectation that if members of the public can contribute to the 
welfare of each other by sharing data, then they feel a moral 
obligation to do so. We could reinterpret this as the principle of 
beneficence, which urges us to act, where we can, to promote 
good.
Willingness to share data rarely led to unqualified support of 
the schemes designed to enable secondary use. Support was 
withheld because, in practice, it was felt that key values would 
not, or could not, be ensured, thus bringing with it the risk of 
individual and collective harm. The public might feel justified 
in objecting to irresponsible, or insecure use of data because 
it is likely to cause individual harm; a direct violation of the 
principle of non-maleficence. Similarly, the use of data for 
private gain may be said to be in violation of the principle of 
justice because it is generally unfair to exploit something for 
reasons other than what it was intended for. Finally, the use of 
patient data without transparency or consent may be seen to 
violate the principle of respect for autonomy.
Strengths and limitations
We conducted a wide search and sifted a huge number of papers, 
including grey literature reports. The search was challenging due 
to wide range of terms used within the literature for secondary 
data usage, and for expressing the concept of public opinion and 
attitudes. We cast a wide net and spent time excluding papers, 
and believe this review encompasses all available research 
meeting our criteria up until the search was conducted. Our 
findings were deliberately limited to UK and the Republic of 
Ireland to create a manageable, relevant and comparable body of 
literature. This enabled us to look for underlying principles for 
publics exposed to a particular type of healthcare system, but 
findings are obviously only applicable within these contexts. 
There may also have been differences between UK and Irish 
respondents due to differences in these healthcare systems. Both 
systems have a general practice plus hospital system. However, 
in the UK, all GP and hospital visits are free at the point of use, 
whereas in Ireland, around two thirds of the population must 
pay a fee for GP or hospital care. This financial transaction may 
influence how patients perceive ownership and use of their medical 
data, although we found no literature on this.
Synthesis of results was also challenging as there was a wide 
range of study types, using different methods. The small, 
convenience samples and low response rates in the majority of 
studies is also likely to have introduced bias into the findings, 
as it is probable that only members of the public most interested 
in the issues consented to take part in the research. This means 
that each study likely represents a narrow range of views, and 
views expressed may have been influenced by the means of data 
collection. It is not clear how this might have affected results 
across the whole range of studies, but it is likely that the themes 
and views represented here are not a complete picture of the 
public’s opinions. This may have contributed to the inability 
to find systematic differences in views between demographic 
groups. Additionally, certain research questions of particular 
interest were not asked of participants and therefore our under-
standing of public opinion is still limited. One example of this is 
whether the use of medical text (in contrast to structured data 
in medical records) elicits specific privacy concerns for the 
public.
Our analysis was informed and influenced by our respective 
backgrounds in philosophy, psychology and epidemiology. 
While attempting to be data-led, we must acknowledge that we 
may not have been wholly neutral in approach. However, our 
review highlights similar themes to Aitken et al.13, suggesting a 
consistency with other syntheses in this area.
Future directions
This review demonstrates and makes explicit the extent to which 
public attitudes to sharing health data are based on reasoning 
in line with established bioethics principles. Decision makers, 
who evaluate data-sharing proposals can therefore draw on an 
explicit framework of ethical principles to address challenges 
around the sharing of patient data. It is becoming increasingly 
accepted that the use of patient data for research or for the 
development of novel healthcare technologies should be sup-
ported by a social licence to operate9. According to social licence 
theory, the public expect that organisations who are institut-
ing potentially controversial schemes (such as patient data shar-
ing) will go beyond the requirements of formal regulation and 
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adhere to voluntary codes of trustworthy behaviour51. Where the 
public are satisfied that the motivations of the organisation are 
trustworthy, they confer a “social licence” to operate. It has been 
hypothesised that previous patient data-sharing initiatives, such 
as Care.data, have failed to secure public support because they 
lacked a social licence for their operation9. 
Public views are complex, and interpreting them to guide policy 
can be difficult. A simple and explicit framework may act as a 
focussing lens, reducing complexity by pulling out underpinning 
moral principles in participants’ views. Establishing core values 
held by the public may facilitate identification of the types of 
safeguards which could help to secure a social licence for 
sharing patient data. We make recommendations about how pub-
lic views could fit into the four tenets of the Beauchamp and 
Childress framework, and could be used to guide decision mak-
ers or regulators. We phrase these suggestions as guiding 
questions, which could be asked of research proposals by ethics 
committees and regulators.
1.   Do the methods of data collection and usage in the 
proposal respect individual patient autonomy? (Respect 
for Autonomy)
Patient autonomy can only be achieved if inclusion of stakehold-
ers and transparency of motivation and data flows are assured at 
all parts of the research process, from study design, through 
ethics approvals, to analysis and interpretation of results52. It is 
also essential that individuals have the possibility to opt-out 
of any data collecting schemes. Notably, the opt-out is only a 
meaningful way of ensuring individual autonomy if transpar-
ency of data usage, and stakeholder inclusion, is guaranteed. This 
combination (opt-out plus full transparency) is also the pub-
lic’s preferred approach53,54, and is thus vital for maximising 
public trust, and securing a social licence, for any initiative. One 
example of operationalising a transparent patient opt out was 
launched by the NHS in the UK in May 2018. Known as the 
National Data Opt-Out55, it was originally recommended and 
designed by the UK National Data Guardian’s Office.
2.    Are the objectives and the intended outputs primarily 
concerned with contributing to the public good? Do they 
have clear scientific value? (Beneficence)
3.    Is any agreement between the NHS and organisations 
providing analytics (private or public) fair and just? 
(Justice)
One almost universal finding was that the public generally 
support research using patient data if the research is for the com-
mon or public good. They tend not to support research using 
patient data which enables private companies to increase profits. 
Thus, to retain a social licence, ethical bodies and regulators 
must evaluate proposals on the basis of their intended aims 
and whether they contribute significantly towards the common 
good. The engagement of industry and private companies to 
provide data analytics will be crucial to maximise benefits from 
patient data in the future. Where private companies are involved, 
there should be clear and transparent communication to all 
stakeholders about how a fair settlement has been negotiated, so 
that the public and patients benefit from the data usage as well 
as the company. Benefits which come from patient data research 
should additionally be publicised and communicated, so that 
these common gains become part of the public consciousness. 
Examples of good practice in this sphere can be seen in the UK 
Farr Institute56 and the Wellcome Trust Initiative “Understanding 
Patient Data”57.
4.    Could granting access to the data, or granting a 
particular use of the data, lead to individual or collective 
harm? (Non-maleficence)
Participants in the studies we reviewed articulated a range of 
harms that they fear could arise from re-use of patient data. 
Possible risks may include individual harms, such as re-iden-
tification and discrimination from insurance companies or 
government agencies. However, ethical bodies and regulators 
should also consider the risk of collective harms from pursuing 
certain research agendas. For example, failure to achieve fair-
ness or transparency in data-sharing agreements may result in 
a loss of public trust in the endeavours of research, or in public 
institutions’ policies on keeping data safe. Such a loss of pub-
lic trust would put at risk any gains made in securing a social 
licence for sharing patient data. In addition, infrastructure put in 
place to safeguard patient privacy must be made transparent to 
stakeholders to increase trustworthiness. These may include 
high standards for data storage security, restrictions on data 
linkage where necessary, evaluation of analytical methods, and 
consistently applied sanctions for any breaches in data security.
Conclusions
Our interpretation of a range of studies of public views 
suggests that the public generally support the use of patient data 
for research purposes. However, the public demand that projects 
of this nature are conducted in a secure way to prioritise privacy, 
and minimise individual and collective harm; that projects set 
research objectives (or negotiate agreements with third parties) 
which are primarily concerned with contributing to the common 
good; and that they do this in a spirit of transparency and inclu-
sivity of stakeholder views. So long as these values are main-
tained, it is likely that the majority of the public will willingly 
share their patient data for research purposes.
We have shown that public thinking about the privacy issues 
around sharing patient data for research maps onto established 
biomedical ethical principles, and such understanding may 
help researchers or regulators to identify how the public comes 
to confer a social licence on patient data research. These core 
principles can be developed to frame guidance for data custo-
dians, regulators and researchers when planning or approving 
research projects using patient data.
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This paper on public opinions about the use of patient data provides a comprehensive overview of
relevant studies. The synthesis covers significant ground in drawing together findings from a mix of study
designs. Despite long-standing debates in this area, the topic continues to be of importance for policy and
practice. Please see some suggestions for improvement below.
 
Perhaps revise some of the full quotes provided in the introduction so that the text flows better.
 
Can you please elaborate on how this review differs from existing systematic reviews on this topic and its
contribution to knowledge?
 
The paper follows systematic processes for literature searching and screening. The approach to
analysing the data has been methodical. More explanation is needed on whether the paper has followed
any established approaches for systematically reviewing mixed methods, secondary data (e.g. see
Dixon-Woods et al. (2005)  or Thomas and Harden (2008) ) and if not, why not. Could you please
provide more details on the following: ‘we undertook a deeper analysis of meaning within findings guided
by both metasynthesis principles  and established principles of bioethics ’.
 
Please elaborate on the application of the Mixed Methods Appraisal Tool (MMAT) for assessing quality
across different study designs. The findings section draws heavily on qualitative data, however, these
studies tend to be ranked lower in terms of ‘quality’ – are studies being prioritised based on a hierarchy of
evidence or are they judged based on the merit of each study design, and what does this mean for the
topic studied here? How has the study using Twitter data been assessed for quality and inclusion (e.g. is
it clear whether participants are from the UK or Ireland for example)?
 
Please revise the PRISMA diagram to clarify which studies were only quantitative, which were only
qualitative and which were mixed methods (these numbers are provided correctly in the text).
It is difficult to interpret syntheses of results presented as a list of percentages e.g. ‘Among the
quantitative studies, public support for a national EHR system was reported at 62.5% , 62.47% , and
81% , while support for sharing information in general was reported 73% .’ What do the authors mean
by national EHR system, what does ‘public support mean’, what does ‘sharing information’ mean and
what do these percentages refer to? Of course these terms are artifacts of the studies reviewed here but it
would be helpful to provide more context for the reader who has not seen the original studies, when
presenting percentages across the document.
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There are differences in the healthcare and EHR systems across the UK and Ireland – it would be worth
reflecting on this when synthesising results from different studies.
 
Academic literature on privacy may help clarify some of the nuances around control and
self-determination (e.g. when it is mentioned that ‘Privacy was widely conceptualised as a process
whereby an individual determines for themselves what happens with the information relating to them.’)
Further use of background literature and theory could inform the analysis.
 
It would be useful to elaborate on the use of the Beauchamp and Childress framework. Are there any
pre-existing applications of this framework to study patient attitudes? How do the nine questions used for
data analysis fit with the Beauchamp and Childress framework? Was the framework used as part of the
analysis or as a lens to discuss the findings? If the latter, more extensive and critical discussion is needed
– perhaps reflecting on how normative ethical frameworks can encompass the messiness of everyday
reality and practice.
 
The paper mentions contradictions between studies based on demographic characteristics. It would be
useful to reflect on why these differences may have occurred and how qualitative data could help explain
them.
 
The future directions section needs further development – this links back to the use of the Beauchamp
and Childress framework. The authors present 4 questions for policy and practice but may need to further
clarify how these would be used, how some of the terms need to be understood (e.g. what constitutes
patient autonomy is in itself a challenging topic of philosophical contention) and whether the answer to
these 4 questions could ever be straightforward in practice.
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 I have read this submission. I believe that I have an appropriate level of expertise to confirm that
it is of an acceptable scientific standard, however I have significant reservations, as outlined
above.
Author Response 04 Jan 2019
, Brighton and Sussex Medical School, UKElizabeth Ford
We would like to thank you for these very helpful comments, which have enabled us to
substantially improve the paper. We spent a lot of time discussing these insightful comments in
order to best make improvements to the manuscript. We detail point by point below how we have
addressed each comment. We have highlighted our changes in our revised manuscript in red font.
1) Perhaps revise some of the full quotes provided in the introduction so that the text
flows better.
We have completely updated the paragraph with the quotes, to reflect new changes in the law due
to GDPR. No quotes are included in the new paragraph (page 3). 
2) Can you please elaborate on how this review differs from existing systematic reviews
on this topic and its contribution to knowledge?
We have added a new section on this on page 4 in the “Striking a balance” paragraph. We have
described how by using a well-recognized ethical framework we can draw underlying themes from
the results which may help to organize policy.
3) More explanation is needed on whether the paper has followed any established
approaches for systematically reviewing mixed methods, secondary data (e.g. see
Dixon-Woods et al. (2005) or Thomas and Harden (2008)) and if not, why not. Could you
please provide more details on the following: ‘we undertook a deeper analysis of meaning
within findings guided by both metasynthesis principles and established principles of
bioethics’. 
We have included a new section on data synthesis in the methods section page 6, outlining how
we used a thematic analysis to interpret the data (a method recommended by both Dixon-Woods
et al. and Thomas and Harden). We have extended this section to explain how the Beauchamp
and Childress framework informed our analysis.
4) Please elaborate on the application of the Mixed Methods Appraisal Tool (MMAT) for
assessing quality across different study designs. The findings section draws heavily on
qualitative data, however, these studies tend to be ranked lower in terms of ‘quality’ – are
studies being prioritised based on a hierarchy of evidence or are they judged based on
the merit of each study design, and what does this mean for the topic studied here? How
has the study using Twitter data been assessed for quality and inclusion (e.g. is it clear
whether participants are from the UK or Ireland for example)?
We treated insights from qualitative and quantitative studies as having different roles but equal
value in our enquiry, and therefore if they met MMAT criteria we did not further
differentiate between methodologies in terms of a hierarchy. We have explained this on page 6.
5) Please revise the PRISMA diagram to clarify which studies were only quantitative,
which were only qualitative and which were mixed methods (these numbers are provided
correctly in the text).
 We have revised the PRISMA diagram as requested (supplementary file 2)
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  We have revised the PRISMA diagram as requested (supplementary file 2)
6) It is difficult to interpret syntheses of results presented as a list of percentages e.g.
‘Among the quantitative studies, public support for a national EHR system was reported at
62.5% , 62.47% , and 81% , while support for sharing information in general was
reported 73% .’
We revised the reporting of results in this section, because, when we considered its value within
the paper, we found the sentence that the reviewer referred to did not answer any of the outlined
research objectives. We now only present evidence on participants’ willingness to share their
patient data for research in this section.
7) There are differences in the healthcare and EHR systems across the UK and Ireland – it
would be worth reflecting on this when synthesising results from different studies.
We have added a paragraph reflecting on the differences in the two systems and how this could
influence results. Page 24.
8) Academic literature on privacy may help clarify some of the nuances around control
and self-determination (e.g. when it is mentioned that ‘Privacy was widely conceptualised
as a process whereby an individual determines for themselves what happens with the
information relating to them.’) Further use of background literature and theory could
inform the analysis.
We have added a paragraph in the discussion on pages 22-23, to describe further literature on the
nuances around the conceptualisation of privacy.
9) It would be useful to elaborate on the use of the Beauchamp and Childress framework.
Are there any pre-existing applications of this framework to study patient attitudes? 
We reference the Beauchamp and Childress framework, but note its similarity to other ethical
principles such as Belmont. While we have not found such basic principles applied to study patient
attitudes (now explained on page 6), we have found them applied to information technology
research (Menlo report, now described and referenced, page 4). We used this simple framework to
cast a lens on the findings of our review, as a way of sorting and filtering through the complexity of
public opinions. A stable and concise framework might enable policy makers and regulators to
more efficiently apply stakeholder views to their decision making, thus facilitating securing a social
license for research.
10) How do the nine questions used for data analysis fit with the Beauchamp and
Childress framework? 
The nine questions for the data analysis were driven by the problem of data sharing for health
research as it manifested itself, rather than our interpretation of the problem through the
Beauchamp and Childress framework. They represent the first iteration of our search for themes
within the data. We have made this clearer on page 6. Our assimilation of the results was
data-driven, and Beauchamp and Childress only used to add the highest levels of interpretation.
11) Was the framework used as part of the analysis or as a lens to discuss the findings? If
the latter, more extensive and critical discussion is needed – perhaps reflecting on how
normative ethical frameworks can encompass the messiness of everyday reality and
practice.
We have provided much more clarity on our use of this framework, on page 4. We say: “We use
these widely accepted principles as a tool to identify patient reasoning in the analysis, and
additionally as a lens to discuss the findings in terms of the newly adopted social license theory for
patient data research. Identifying a framework which describes the core moral or ethical values
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 patient data research. Identifying a framework which describes the core moral or ethical values
underlying public views may help us to understand approaches to sharing patient data for research
that the public will deem as acceptable, and help us to predict the reaction of the public to new data
sharing challenges in the future.”
 12) The paper mentions contradictions between studies based on demographic
characteristics. It would be useful to reflect on why these differences may have occurred
and how qualitative data could help explain them.
In our investigation of differences in views by demographic characteristics, we did not find any
replicable trends across quantitative studies. This may be because quantitative studies were
limited in their ability to rigorously identify differences, or because such difference do not exist.
Therefore we cannot speculate on reasons for differences, because we have not got any firm
evidence that these differences exist. We have added a sentence on this to the discussion. Page
24.
 13) The future directions section needs further development – this links back to the use of
the Beauchamp and Childress framework. The authors present 4 questions for policy and
practice but may need to further clarify how these would be used, how some of the terms
need to be understood (e.g. what constitutes patient autonomy is in itself a challenging
topic of philosophical contention) and whether the answer to these 4 questions could ever
be straightforward in practice.
Many thanks for these suggestions. We have substantially re-written this section. 
 No competing interests were disclosed.Competing Interests:
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 Sarah Cunningham-Burley
Usher Institute, Edinburgh Medical School, University of Edinburgh, Edinburgh, UK
On the whole this is a clearly presented systematic review (a copy edit is required as there are a few
typos) and it reinforces the findings of a similar systematic review that I am co-author on, as the authors
note in their conclusion. However, this review included quantitative studies and focused only on UK and
Ireland, so the articles included do not fully overlap - the reviews were different in scope. So this is an
additional contribution to the literature on public attitudes to data linkage and sharing for health research. 
The process of the systematic review is delineated well and there is sufficient information on each
included article for the reader to be able to access these and also to relate the findings of the review to
those articles.  The authors also cite some other relevant literature not included in the review. The authors
are appropriately cautious in their interpretation of the findings from various studies, as these are often
small scale, limited response rates etc. 
I have a few concerns about the paper. The authors do not seem to be aware of existing governance
structures, carefully developed alongside research on public attidues and legal and ethical analyses.
Health is a devolved matter in the UK. They need to read and make reference to the Scottish
Government’s Data Linkage Framework ( ),http://www.gov.scot/Topics/Statistics/datalinkageframework
the Guiding Principles for Data Linkage, and the terms of reference for the Public Benefits and Privacy
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 the Guiding Principles for Data Linkage, and the terms of reference for the Public Benefits and Privacy
Panel for Health and Social Care. Perhaps also look at the FARR Institute website to see how this major
initiative is promoting safe use of health data for research purposes. There are some key reports that have
not been identified by their search that are highly relevant: Public Acceptability of Cross-Sectoral Data
Linkage ( ); Public acceptability of data sharing betweenhttp://www.gov.scot/Publications/2012/08/9455
public, private and third sectors for research purposes (http://www.gov.scot/resource/0043/00435458.pdf
); Aitken et al (2011) .
These would all help the authors craft more apposite recommendations. 
A few other points – while supportive of an approach that identifies core principles, I’m not sure that
Beauchamp and Childress’ four principles for biomedical research translate as easily as they suggest. I
think some reference to emergent frameworks that speak to a social licence might be more compelling
and the core principles that might underpin such a license. Public health ethics might help here. 
A more minor point – the authors start by referring the medical data but really they are focussed on health
data – a broader term. I also wonder why they use the term public opinion instead of attitudes. It may be
that these terms are used differently in quantitative and qualitative research perhaps, but some
justification would be helpful. During the presentation of the findings of the review, they also refer to GP
records, the Electronic Health Record, Cancer Registries – maybe clarify what type of records the studies
they are referring to – or use the overarching term of EHR. The authors touch on the differences in the
way in which public’s views are accessed and I think that point bears further elaboration.
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I have read this submission. I believe that I have an appropriate level of expertise to confirm that
it is of an acceptable scientific standard, however I have significant reservations, as outlined
above.
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 Author Response 04 Jan 2019
, Brighton and Sussex Medical School, UKElizabeth Ford
Many thanks for your helpful comments which have enabled us to substantially improve the paper.
We detail point by point below how we have addressed each comment. We have highlighted our
changes in the manuscript in red font.
1) Copy edit is required. 
Thank you, we have thoroughly proofread the paper.
2) The authors do not seem to be aware of existing governance structures, carefully
developed alongside research on public attidues and legal and ethical analyses. Health is
a devolved matter in the UK. They need to read and make reference to the Scottish
Government’s Data Linkage Framework
(http://www.gov.scot/Topics/Statistics/datalinkageframework), the Guiding Principles for
Data Linkage, and the terms of reference for the Public Benefits and Privacy Panel for
Health and Social Care.
Thank you for pointing out the regional differences and the link to the Scottish framework. We have
replaced this section with a general overview of the new EU GDPR legislation (page 3) and its
general implications for the sharing of patient data, with no references made to specific countries’
frameworks or data access policies.
3) Perhaps also look at the FARR Institute website to see how this major initiative is
promoting safe use of health data for research purposes
We have included reference to Farr, and the Wellcome trust initiative Understanding Patient Data
as key exemplars of disseminators of public benefits of patient data research, in the discussion
page 25
4) There are some key reports that have not been identified by their search that are highly
relevant: Public Acceptability of Cross-Sectoral Data Linkage
(http://www.gov.scot/Publications/2012/08/9455); Public acceptability of data sharing
between public, private and third sectors for research purposes
(http://www.gov.scot/resource/0043/00435458.pdf); Aitken et al (2011) .
recommendations. 
Many thanks for suggesting these reports. We scrutinised these reports in detail and found they did
not meet our eligibility criterion that studies must be about sharing health data in particular and not
personal data in general.
5) A few other points – while supportive of an approach that identifies core principles, I’m
not sure that Beauchamp and Childress’ four principles for biomedical research translate
as easily as they suggest. I think some reference to emergent frameworks that speak to a
social licence might be more compelling and the core principles that might underpin such
a license. Public health ethics might help here. 
Many thanks for these suggestions which mirror recommendations from reviewer 1 and have
helped us to strengthen the main messages of the paper. We have substantially rewritten the future
directions section and the majority of the discussion. We have given more background information
on the use of key ethical principles such as Beauchamp and Childress in the introduction, and have
related these principles to social license theory throughout the paper.
6) A more minor point – the authors start by referring the medical data but really they are
focussed on health data – a broader term. I also wonder why they use the term public
1
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 focussed on health data – a broader term. I also wonder why they use the term public
opinion instead of attitudes. It may be that these terms are used differently in quantitative
and qualitative research perhaps, but some justification would be helpful.
Papers used a variety of different terms denoting that they were capturing the thoughts of patients
and the public, including: views, perspectives, attitudes, perceptions, opinions, acceptance,
awareness, thoughts. We have decided to use generically the term public “views” because this
feels like the most general term, and we have made this consistent throughout.
We agree with the reviewers on the need for clarification of the terms medical and health data. We
have described the type of data we are focusing on in the methods (page 5), as “electronic hospital
records, electronic general practice records, and data extracted from these records, for example
cancer registries and national disease databases” and have used the terms patient data or EHRs
to represent these data throughout the manuscript. We preferred the term “patient data” to keep
our language consistent with public facing initiatives such as the Wellcome Trust “Understanding
Patient Data” initiative.
7) During the presentation of the findings of the review, they also refer to GP records, the
Electronic Health Record, Cancer Registries – maybe clarify what type of records the
studies they are referring to – or use the overarching term of EHR. The authors touch on
the differences in the way in which public’s views are accessed and I think that point
bears further elaboration.
Please see response to the point above regarding terms for patient data. We have added a
sentence to the limitations about how the views expressed may have been affected by methods of
studies. (Page 24) 
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